About this Series

Hormone receptor–positive is the most common breast cancer, accounting for approximately 80% of all cases. Although metastatic HR+/HER2- breast cancer remains incurable, it is increasingly manageable. Expanded treatment options, including targeted agents used in combination with endocrine therapy, are extending the lives of women with metastatic breast cancer, and careful monitoring of biomarkers helps indicate when it is appropriate to change therapies. Increased emphasis on diet and exercise, psychosocial support, and symptom management—especially of bone metastases—contributes to an increased quality of life for women with metastatic disease.

Experts at Dana-Farber Cancer Institute discuss the ways in which treatment of HR+/HER2- metastatic breast cancer is evolving into an individualized approach, and how metastatic breast cancer patients are taking an active role as partners in the research of their disease.

Show More

Who's Who
{{#each bp-whos-who.people}}
{{{name}}} {{{addComma prof}}}
{{#if disclosureTitle }} Disclosure
More on Metastatic Breast Cancer